Intrathecal Analgesia Effects on Cancer Patients Discomfort Symptoms — IT-ESAS  

Refractory Cancer Pain Clinical Trial

Official title: Evaluation of Discomfort Symptoms in Patients With Refractory Cancer Pain and Intrathecal Analgesia Management

Status Completed

Clinical Trial Summary

Intrathecal analgesia is used in refractory cancer pain because of drug sides effects or intractable pain. The aim of this approach is to improve pain management, and also to improve patient comfort. This study will assess patient discomfort symptoms before and after setting up intrathecal analgesia.

Clinical Trial Description

Descriptive multicenter study including patients with refractory cancer pain (unmanageable drug sides effects or intractable pain) who will receive intrathecal analgesia Patient discomfort symptoms will be evaluated before and after the beginning of intrathecal analgesia at 15, 30, 60 and 90 days.

Moreover, the impact on patient close relatives and on return home will be assessed. ;

Related Conditions & MeSH terms

• Cancer Pain
• Intrathecal Analgesia
• Refractory Cancer Pain

• NCT number: NCT04491123
• Study type: Observational
• Source: University Hospital, Montpellier
• Status: Completed
• Start date: November 1, 2018
• Completion date: June 30, 2020